Optimal antiplatelet treatment for percutaneous coronary intervention: Clopidogrel vs. ticlopidine

International Journal of Cardiology

Volumn 114, Issue 1, 2007, Pages 101-102

  Almsherqi, Zakaria A ^a   McLachlan, Craig S ^b   Mossop, Peter ^b   Deng, Yuru ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ST VINCENT S HOSPITAL   (Australia)

Author keywords

Antiplatelet treatment; Clopidogrel; Percutaneous coronary intervention; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TICLOPIDINE;

APLASTIC ANEMIA; ARTICLE; DRUG SAFETY; HUMAN; NEUTROPENIA; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; THROMBOCYTOPENIC PURPURA; THROMBOSIS; TREATMENT DURATION; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY THROMBOSIS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 33751309342     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2005.09.052     Document Type: Article

References (15)

1. Wolak A., Amit G., Cafri C., Gilutz H., Ilia R., and Zahger D. Increased long term rates of stent thrombosis and mortality in patients given clopidogrel as compared to ticlopidine following coronary stent implantation. Int J Cardiol 103 3 (2005) 293-297
2. Schomig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med 334 (1996) 1084-1089
3. Wysowski D.K., and Bacsanyi J. Blood dyscrasias and hematologic reactions in ticlopidine users. JAMA 276 (1996) 952
4. Prescribing information: ticlid (ticlopidine hydrochloride) tablets. Physicians Desk Reference (2004), Medical Economics Co, Montvale, NJ
5. Besson G., and Bogousslawsky J. Current and future options for the prevention and treatment of stroke. CNS Drugs 3 (1995) 351-362
6. Schror K. Antiplatelet drugs: a comparative review. Drugs 50 (1995) 7-28
7. Bennett C.L., Connors J.M., and Moake J.L. Clopidogrel and thrombotic thrombocytopenic purpura. N Eng J Med 343 (2000) 1193-1194
8. Makkar R., Eigler N., Kaul S., Zeng H., Herbert J.M., and Litvack F. Clopidogrel, a novel platelet ADP receptor antagonist inhibits aspirin and ticlopidine resistant stent thrombosis. J Am Coll Cardiol 29 (1997) 353A [suppl A]
9. Moussa I., Oetgen M., Roubin G., et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 99 18 (May 11 1999) 2364-2366
10. Muller I., Besta F., Schulz C., Massberg S., Schonig A., and Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 89 5 (May 2003) 783-787
11. Hochholzer W., Trenk D., Frundi D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 20 (May 24 2005) 2560-2564
12. Gurbel P.A., Bliden K.P., Hiatt B.L., et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107 (2003) 2908-2913
13. Neubauer H., Gunesdogan B., Hanefeld C., Spiecker M., and Mugge A. Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function: a flow cytometry study. Eur Heart J 24 19 (2003) 1744-1749
14. Lau W.C., Waskell L.A., Watkins P.B., et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107 1 (2003) 32-37
15. Almsherqi Z.A., McLachlan C., Mossop P.J., and Deng Y. Evaluation of clopidogrel resistance. Thromb Res. 116 5 (2005) 451-453